Oral and Intravenous Chloramphenicol
Oral and intravenous chloramphenicol should be avoided where possible during breastfeeding.
Variable chloramphenicol levels have been found in breast milk after oral administration. Levels have ranged from 0.3–8.5% of the weight-adjusted maternal dose. There are no studies looking at milk levels after intravenous administration.
Oral and intravenous chloramphenicol are associated with serious haematological side-effects when administered directly. Although such adverse effects have not been reported in breastfed infants, they represent significant risk. In particular, there is an increased risk of aplastic anaemia. This effect is not thought to be dose-related, and therefore might occur as a result of exposure via breastfeeding.
Grey Baby Syndrome
An additional concern with chloramphenicol use is Grey Baby Syndrome. Chloramphenicol can cause toxicity in some premature and young infants because their underdeveloped liver enzymes are unable to metabolise (break down) the drug properly. Symptoms of Grey Baby Syndrome include grey skin colour, abdominal distention, vomiting, flaccidity and breathing difficulties. However, this has not been reported as a result of exposure from breastfeeding.
One study reported several side-effects in breastfed infants following maternal exposure to oral chloramphenicol in doses ranging from 1-3g daily. Side-effects reported were poor sucking, somnolence, vomiting, and excessive abdominal gas and distension. No other studies have reported infant side-effects from chloramphenicol exposure through breast milk.
Chloramphenicol eye and ear preparations can be used with caution during breastfeeding. However, they should not be used in individuals where there is a past or family history of blood dyscrasias. Fusidic acid or gentamicin preparations would be preferred, if clinically appropriate.
There are no data available on the levels of chloramphenicol in breast milk after topical administration of chloramphenicol whilst breastfeeding. Based on the drug properties, and minimal absorption, levels are predicted to be very low.
There is conflicting evidence regarding whether topical chloramphenicol can cause aplastic anaemia. Therefore there is still a theoretical risk that the very low amounts of chloramphenicol which may pass into the breast milk from topical formulations could cause aplastic anaemia.
No side-effects have been reported in breastfed infants who have been exposed to topical chloramphenicol.
Monitoring the infant
If the mother uses topical chloramphenicol, the infant should be monitored for the following side-effects as a precautionary measure:
- abdominal distension
- poor feeding
- difficulty breathing
- vomiting or diarrhoea
- ashen grey skin colour
This will quickly pick up any potential issues. Usually, further investigation is required before attributing any side-effects to the medicine.
Patient information is available regarding the use of topical chloramphenicol, including use in breastfeeding, on the NHS website.
Recommendations apply to full-term and healthy infants. If the infant was born prematurely or unwell, or if multiple medicines are being taken, or if oral or intravenous chloramphenicol is required, contact the UK Drugs in Lactation Advisory Service.
Besamusca FW, Bastiaensen LA. Blood dyscrasias and topically applied chloramphenicol in ophthalmology. Doc Ophthalmol 1986;64:87–95.
Brayfield A (ed), Martindale: The Complete Drug Reference, updated periodically. London: Pharmaceutical Press. Available from www.medicinescomplete.com [accessed on-line 19/11/2021]
Chin KG, McPherson CE, Hoffman M et al. Use of anti-infective agents during lactation: Part 2 – Aminoglycosides,Macrolides, Quinolones, Sulfonamides, Trimethoprim, Tetracyclines, Chloramphenicol, Clindamycin and Metronidazole. The Journal of Human Lactation 2001;17(1): 54-65.
Fraunfelder FT, Morgan RL, Yunis AA. Blood dyscrasias and topical ophthalmic chloramphenicol. Am J Ophthalmol 1993; 115: 812–3.
Gray C. Systemic toxicity with topical ophthalmic medications in children. Paed Perinat Drug Ther 2006;7:23–29.
Havelka J, Frankova A. [Adverse effects of chloramphenicol in newborn infants]. Cesk Pediatr. 1972;27:31–3.
Havelka J, Hejzlar M, Popov V et al. Excretion of chloramphenicol in human milk. Chemotherapy 1968;13:204-211.
Kasten MJ. Symposium on antimicrobial agents—part XI: clindamycin, metronidazole, and chloramphenicol. Mayo Clin Proc 1999;74:825–833.
Matsuda S. Transfer of antibiotics into maternal milk. Biol Res Pregnancy Perinatol 1984;5:57–60.
McGhee CN, Anastas CN. Widespread ocular use of topical chloramphenicol: Is there justifiable concern regarding idiosyncratic aplastic anaemia? Br J Ophthalmol 1996;80:182–184.
Plomp TA, Thiery M, Maes RAA. The passage of thiamphenicol and chloramphenicol into human milk after single and repeated oral administration. Vet Hum Toxicol 1983;25:167–172.
Smadel JE, Woodward TE, Ley HL et al. Chloramphenicol in the treatment of Tsutsugamushi disease (Scrub typhus). J Clin Invest 1949;28:1196–1215.
Trope GE, Lawrence JR, Hind VMD, et al. Systemic absorption of topically applied chloramphenicol eyedrops. Br J Ophthalmol 1979;63:690–691.
Ursell P. Widespread use of topical chloramphenicol. Br J Ophthalmol 1996; 80:854.
Walker S, Diaper CJM, Bowman R et al. Lack of evidence for systemic toxicity following topical chloramphenicol use. Eye 1998;12:875–879.